FDA Data Show Problems With Shanghai Trial Of Pfizer/BMS’ Eliquis
This article was originally published in PharmAsia News
Executive Summary
A Shanghai trial of Eliquis, the apixaban blood thinner marketed by Bristol-Myers Squibb and Pfizer, apparently led to some participants receiving the wrong drug and trial records being altered, according to U.S. FDA documents.